285 related articles for article (PubMed ID: 28106467)
21. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.
Béguelin W; Teater M; Meydan C; Hoehn KB; Phillip JM; Soshnev AA; Venturutti L; Rivas MA; Calvo-Fernández MT; Gutierrez J; Camarillo JM; Takata K; Tarte K; Kelleher NL; Steidl C; Mason CE; Elemento O; Allis CD; Kleinstein SH; Melnick AM
Cancer Cell; 2020 May; 37(5):655-673.e11. PubMed ID: 32396861
[TBL] [Abstract][Full Text] [Related]
22. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
Krysiak K; Gomez F; White BS; Matlock M; Miller CA; Trani L; Fronick CC; Fulton RS; Kreisel F; Cashen AF; Carson KR; Berrien-Elliott MM; Bartlett NL; Griffith M; Griffith OL; Fehniger TA
Blood; 2017 Jan; 129(4):473-483. PubMed ID: 28064239
[TBL] [Abstract][Full Text] [Related]
23. H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas.
Brune MM; Vela V; Bratic Hench I; Dertinger S; Borgmann V; Dirnhofer S; Tzankov A
Virchows Arch; 2022 Sep; 481(3):489-497. PubMed ID: 35661922
[TBL] [Abstract][Full Text] [Related]
24. [INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].
Kwiatek M; Pruchniewski Ł; Kwiatek J; Kaźmierczak M; Lewandowski K
Wiad Lek; 2018; 71(5):1095-1098. PubMed ID: 30176648
[TBL] [Abstract][Full Text] [Related]
25. Genetic and epigenetic inactivation of
Oricchio E; Katanayeva N; Donaldson MC; Sungalee S; Pasion JP; Béguelin W; Battistello E; Sanghvi VR; Jiang M; Jiang Y; Teater M; Parmigiani A; Budanov AV; Chan FC; Shah SP; Kridel R; Melnick AM; Ciriello G; Wendel HG
Sci Transl Med; 2017 Jun; 9(396):. PubMed ID: 28659443
[TBL] [Abstract][Full Text] [Related]
26. Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma.
Larrea E; Fernandez-Mercado M; Guerra-Assunção JA; Wang J; Goicoechea I; Gaafar A; Ceberio I; Lobo C; Okosun J; Enright AJ; Fitzgibbon J; Lawrie CH
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233721
[TBL] [Abstract][Full Text] [Related]
27. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.
Louissaint A; Schafernak KT; Geyer JT; Kovach AE; Ghandi M; Gratzinger D; Roth CG; Paxton CN; Kim S; Namgyal C; Morin R; Morgan EA; Neuberg DS; South ST; Harris MH; Hasserjian RP; Hochberg EP; Garraway LA; Harris NL; Weinstock DM
Blood; 2016 Aug; 128(8):1093-100. PubMed ID: 27325104
[TBL] [Abstract][Full Text] [Related]
28. CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.
Castillo J; Wu E; Lowe C; Srinivasan S; McCord R; Wagle MC; Jayakar S; Edick MG; Eastham-Anderson J; Liu B; Hutchinson KE; Jones W; Stokes MP; Tarighat SS; Holcomb T; Glibicky A; Romero FA; Magnuson S; Huang SA; Plaks V; Giltnane JM; Lackner MR; Mounir Z
Cancer Res; 2019 Aug; 79(15):3916-3927. PubMed ID: 31182547
[TBL] [Abstract][Full Text] [Related]
29. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract][Full Text] [Related]
30. EZH2 alterations in follicular lymphoma: biological and clinical correlations.
Huet S; Xerri L; Tesson B; Mareschal S; Taix S; Mescam-Mancini L; Sohier E; Carrère M; Lazarovici J; Casasnovas O; Tonon L; Boyault S; Hayette S; Haioun C; Fabiani B; Viari A; Jardin F; Salles G
Blood Cancer J; 2017 Apr; 7(4):e555. PubMed ID: 28430172
[TBL] [Abstract][Full Text] [Related]
31. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.
Gángó A; Bátai B; Varga M; Kapczár D; Papp G; Marschalkó M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bödör C; Szepesi Á
Virchows Arch; 2018 Oct; 473(4):453-462. PubMed ID: 29858685
[TBL] [Abstract][Full Text] [Related]
32. KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
Vlasevska S; Garcia-Ibanez L; Duval R; Holmes AB; Jahan R; Cai B; Kim A; Mo T; Basso K; Soni RK; Bhagat G; Dalla-Favera R; Pasqualucci L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2218330120. PubMed ID: 36893259
[TBL] [Abstract][Full Text] [Related]
33. The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.
Barasch NJK; Liu YC; Ho J; Bailey N; Aggarwal N; Cook JR; Swerdlow SH
Hum Pathol; 2020 Dec; 106():93-105. PubMed ID: 33045225
[TBL] [Abstract][Full Text] [Related]
34. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
35. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
[TBL] [Abstract][Full Text] [Related]
36. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.
Hellmuth JC; Louissaint A; Szczepanowski M; Haebe S; Pastore A; Alig S; Staiger AM; Hartmann S; Kridel R; Ducar MD; Koch P; Dreyling M; Hansmann ML; Ott G; Rosenwald A; Gascoyne RD; Weinstock DM; Hiddemann W; Klapper W; Weigert O
Blood; 2018 Oct; 132(16):1695-1702. PubMed ID: 30126979
[TBL] [Abstract][Full Text] [Related]
37. Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells.
Makker J; Wotherspoon A; Tzioni MM; Chen Z; Guo S; Jiang D; Casa C; Cucco F; Du MQ
J Pathol; 2024 Mar; 262(3):289-295. PubMed ID: 38156368
[TBL] [Abstract][Full Text] [Related]
38. Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.
Desmots F; Roussel M; Pangault C; Llamas-Gutierrez F; Pastoret C; Guiheneuf E; Le Priol J; Camara-Clayette V; Caron G; Henry C; Belaud-Rotureau MA; Godmer P; Lamy T; Jardin F; Tarte K; Ribrag V; Fest T
Clin Cancer Res; 2019 Jan; 25(2):735-746. PubMed ID: 30348636
[TBL] [Abstract][Full Text] [Related]
39. Clonal evolution and relapse in early-stage follicular lymphoma - a tree with many branches
Fend F; Quintanilla-Martinez L
J Pathol; 2024 Jul; 263(3):271-274. PubMed ID: 38775014
[TBL] [Abstract][Full Text] [Related]
40. The follicular lymphoma epigenome regulates its microenvironment.
Amin R; Braza MS
J Exp Clin Cancer Res; 2022 Jan; 41(1):21. PubMed ID: 35022084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
